Bio-Reference Laboratories, Inc. (NASDAQ:BRLI)

BRLI has a history of steady growth, a dominant role in two niche markets: prisons (nationwide) and the NYC area. And continued attention from two short seller / publishers has driven the short position to 42% of the float. The chances of this going to zero are slim. The chances of the publishers being the first shorts out, ahead of a stampede to close, are great.

BRLI is operating in a long-term trend of increasing health care. It's financial results have shown robust growth trajectories over the last few years. I do not see any reason for this trend to change.

Growth rates > 20%, no debt, lots of cash.

Nasdaq Growth Value Investor Screener:

This came up in a screen for stocks with the highest gains in the last 4 weeks. With a fair book value of $7.28 this company is greatly overvalued. Profitable and an interesting business model, but only has $202 million in shareholders' equity as of 1Q12. Should be an easy red-thumb target.

Bad marketing & commercial practices giving less good financial results !

Bought the stock around $14 wish I found out about it earlier. Strong earnings in a weak economy, great growth stock.

I wish I entered this yesterday...very high growth, over 20% ROE. It's a growth stock, but its P/E is 2/3 of LabCorp's and only about half of Quest Diagnostics. The reason why it's so low is because some short-selling site alleged shady business practices, shorted the stock, then covered its position within the next few days (apparently constant double digit growth for a $400M market cap company in a giant and rapidly expanding industry is cause for alarm). Short % of float is almost 30%, and they just posted record profits. This opportunity won't last long.

HG

Low PEG for 20% Growth

SC QC Limit 21.21

Favorable demographics, smaller company than industry's largest with better growth or acquisition prospects.

I work in Healthcare, this lab has just come into our organization, we currently use labcorp and quest. I started researching bio-referance and it seems a strong company. lots of positives (growth, gendx, cancer research etc). still researching but may grab some today.

gene testing and other niche tests coming into demand

22.97

stock split, and healthcare

People are always having tests done so a company like this is a cash cow. It could be a takeover candidate for Quest or maybe Mr. Buffet may feel warm blooded and buy this body fluid testing company.

This pick based solely on passage of the healthcare bill. Bill passes, millions of new tests will be ordered and this company will most likely prosper; no healthcare bill, business as usual and this company will still do just fine. (Based on the performance and numbers I've seen to date...)

Small cap stock with too good to be true earning performance, maybe that's a warning sign?. While sales and earnings haven't been deterred by this economic downturn, the P/E ratio has been reduced from about 30 to about 20. Expect this company to keep growing at 20%, perhaps P/E will creep back up again, maybe they'll get bought out by a bigger player.